BSD Medical moves closer to HDE for cervical cancer treatment
This article was originally published in The Gray Sheet
Executive Summary
BSD Medical's BSD-2000 hyperthermia system receives a humanitarian use device designation from FDA for use in conjunction with radiation therapy for cervical carcinoma patients ineligible for chemotherapy, the firm announces May 18. The HUD designation, which confirms a target population of fewer than 4,000 U.S. patients annually, is the first step toward seeking Humanitarian Device Exemption marketing approval (1"The Gray Sheet" March 16, 2009, p. 15)
You may also be interested in...
Regulatory News In Brief
HHS creates Recovery Act office: Office of Recovery Act Coordination will "enhance and streamline" HHS' efforts to manage $137 billion in funding granted under the economic stimulus package, according to a March 11 announcement. The new office will be led by Dennis Williams, a 20-year veteran of the department who also will become HHS deputy assistant secretary for recovery act coordination. As of March 11, HHS has distributed $3 billion in Recovery Act funds for programs like Medicaid and Community Health Centers. The stimulus bill was signed by President Obama in February (1"The Gray Sheet" Feb. 16, 2009, p. 3)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.